Therapeutic interfering particles exploiting viral replication and assembly mechanisms show promising performance: a modelling study

Farzad Fatehi1,2,6, Richard J. Bingham1,2,3,6, Pierre-Philippe Dechant1,2,6,6, Peter G. Stockley5 & Reidun Twarock1,2,3

Defective interfering particles arise spontaneously during a viral infection as mutants lacking essential parts of the viral genome. Their ability to replicate in the presence of the wild-type (WT) virus (at the expense of viable viral particles) is mimicked and exploited by therapeutic interfering particles. We propose a strategy for the design of therapeutic interfering RNAs (tiRNAs) against positive-sense single-stranded RNA viruses that assemble via packaging signal-mediated assembly. These tiRNAs contain both an optimised version of the virus assembly manual that is encoded by multiple dispersed RNA packaging signals and a replication signal for viral polymerase, but lack any protein coding information. We use an intracellular model for hepatitis C viral (HCV) infection that captures key aspects of the competition dynamics between tiRNAs and viral genomes for virally produced capsid protein and polymerase. We show that only a small increase in the assembly and replication efficiency of the tiRNAs compared with WT virus is required in order to achieve a treatment efficacy greater than 99%. This demonstrates that the proposed tiRNA design could be a promising treatment option for RNA viral infections.

Viruses are a major burden for public health and economy, yet our repertoire of antiviral options is still very limited. This is, in part, due to the high frequency with which viral genomes mutate and thus evade treatment. On the other hand, these mutations can sometimes lead to the production of defective viral genomes (DVGs) which are shed in defective interfering particles (DIPs). DVGs are spontaneously occurring mutants in a viral infection that lack essential genetic information, e.g. through deletion mutations, but are capable of replicating in the presence of, and indeed at the expense of, resources produced by viruses1,2. Many DVGs are well-known to have a replicative advantage over WT and to play a role in interference with WT virus3,4, virus persistence5 as well as specific6 and unspecific immune activation5,7. The exploitation of DIPs is a promising recent approach for therapy6,8,9. DIPs are selected and amplified for therapeutic use facilitated by advanced cloning techniques6,10–14, and have progressed to the clinic10,15–17.

Von Magnus was the first to report the occurrence of DIPs, seen in influenza A virus populations passaged in embryonated chicken eggs18. Subsequently, in a prolonged persistence of vesicular stomatitis virus infections, mediated by WT DIPs, mutants (called Sdi− mutants) were detected that are WT DIP resistant, demonstrating the importance of selection for DIP populations19. DIPs have been reported to cause oscillations in virus levels20. Zwart et al.21 developed a simple mathematical model of baculovirus-DI dynamics which qualitatively reproduced the oscillatory patterns seen in experimental data. DIPs engineered for therapy were designed to spread between individuals and autonomously target high-risk groups for HIV and it has been argued that this method could decrease HIV/AIDS prevalence by 30-fold in 50 years22,23. The impact of these transmissible antivirals are studied in intracellular, within-host, and epidemiological models24,25.

1York Cross-disciplinary Centre for Systems Analysis, University of York, York YO10 5GE, UK. 2Department of Mathematics, University of York, York YO10 5DD, UK. 3Department of Biology, University of York, York YO10 5DD, UK. 4School of Science, Technology and Health, York St John University, York YO31 7EX, UK. 5Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds LS2 9JT, UK. 6These authors contributed equally: Farzad Fatehi, Richard J. Bingham and Pierre-Philippe Dechant. 25email: p.g.stockley@leeds.ac.uk; rt507@york.ac.uk
We propose here a novel strategy that exploits our discovery of packaging signal (PS)-mediated assembly in single-stranded RNA (ssRNA) viruses for the design of therapeutic interfering RNAs (tiRNAs) which are packaged into therapeutic interfering particles (TIPs) mimicking essential features of these DIPs. The genomes of many RNA viruses, including bacteriophages, plant viruses, and human pathogens present multiple dispersed sequence/structure motifs (PSs) that share a core recognition motif for the viral coat protein (Cp). Sequence variation around that core motif confers differential levels of affinity for Cp to the PSs, creating a hierarchy of affinities across the genome-embedded PS ensemble. This enables PSs to recruit Cp to the growing capsid shell, collectively promoting virus assembly26–32 (Fig. 1a).

Figure 1. Assembly and intracellular dynamics of vRNAs and tiRNAs. (a) The PS-mediated assembly paradigm: Multiple sequence/structure motifs called packaging signals (PSs), that are dispersed throughout the viral genome, promote virion assembly via sequence specific interactions with coat protein (Cp). (b) vRNA and tiRNA in comparison: tiRNA is similar to vRNA but is devoid of any genetic message. (c) Schematic representation of the mathematical model for vRNA (red) and tiRNA (blue) in an HCV infection: In step 1 and 2; vRNA in the cytoplasmic ribosome to form a translation complex, which translocates the viral polyprotein (PP). The latter is cleaved, leading to the production of structural proteins such as core protein (Cp) and nonstructural proteins, including NS3/4A, NS5A, and NS5B. In step 3; NS5B and NS5A bind to vRNA or tiRNA and host factor (HF), respectively. These two complexes are imported into the vesicular membranous structure (VMS). In step 4; the imported RNAs form double-strand RNAs (dsRNAs) and release NS5B and HF. In step 5; dsRNAs again bind to the NS5B and synthesise new vRNAs and tiRNAs. In step 6; these RNAs are either exported into the cytoplasm, or assembled into virions with 180 Cp and exported from the cell. (d) The time evolution of the HCV infection model shows the cumulative number of released virions (solid red line) and total vRNA (dashed red line), averaged over 250 simulations with the initial condition (+) RNA cyt=1 and Cp=180. (e) The dynamics of virions and TIPs, where the solid red and blue lines indicate the released virions and TIPs, respectively, and the dashed red and blue lines the total vRNAs and tiRNAs, respectively, with the initial condition (+) RNA cyt=1, (+) tiRNA cyt=1 and Cp=360. The shaded areas highlight the regions of one standard deviation (std) from the mean. (d) and (e) are plotted using parameter values from Table 1 with ba = 1 and br = 1.

Stochastic simulations of virus assembly reveal that the differences in affinity at distinct PS sites are important, because they bias the number of possible assembly pathways to a small number of dominant ones with very similar geometric properties, resulting in higher yields of fully assembled capsids compared with PS distributions lacking this variation. They also ensure specific encapsidation in the context of cellular competitor RNAs. This means that PSs enable the virus to overcome the equivalent of Levinthal’s Paradox in protein folding. The latter refers to the complexity of protein folding, which would require an unrealistically long time to complete if it solely relied on a random exploration of all combinatorially possible pathways. Similarly, the assembly of a viral capsid would be too slow in the arms race against host defence mechanisms if it were exploring all geometrically possible pathways, rather than the subset favoured due to interaction with the PSs. In some cases, such as in the Picornavirus human parechoviruses (HPeV), the PSs and their Cp binding sites have been characterised to atomistic detail. They have also been identified in hepatitis B virus, a DNA virus that packages its genome into its capsid in the form of pre-genomic RNA. Our detailed mechanistic understanding of PS-mediated assembly has
enabled us to optimise the assembly code in satellite tobacco necrosis virus (STNV), creating RNA mutants that outcompete viral genomes in a competition assay. Many of the best-studied examples of DVGs are found in (-) ssRNA viruses, which are presently known not to assemble via multiple dispersed PSs. For viruses assembling via multiple dispersed PSs, indeed DIPs that are assembly competent and competitive with WT may not spontaneously arise through the standard mechanisms; however, using our new mechanistic understanding they could be engineered. Here we propose to decouple the assembly code from the genetic message, and create synthetic assembly substrates containing only the PS-encoded virus assembly instructions allowing them to be efficiently encapsulated by viral Cp. To mimic the naturally occurring DIPs, we also include a recognition signal for viral replicase into our de novo designed tiRNAs, so that they are replicated by viral replicase (Fig. 1b). Although some naturally occurring DIPs for influenza A or Zika virus have internal ribosome entry site (IRES), we deliberately exclude such IRESs here in order to give tiRNAs another competitive advantage over vRNAs by not spending time on translation. An added advantage is that the presence of IRESs, and consequently interactions between ribosomes and IRES containing tiRNAs, would trigger an immune response that could lead to the removal of the cell, unnecessarily increasing tissue damage.

Mathematical models of a viral infection can be used to assess the merits of novel antiviral strategies. The population dynamics of DIPs interacting with WT virus (called the ‘helper’ or ‘standard’ virus) can be complicated with chaotic or predator-prey dynamics, but often the parasitic relationship between DIPs and helper virus results in the attenuation or clearance of the original infection. Thus, we use HCV (an ssRNA virus) as a model system and we develop an extension of an intracellular model of HCV presented by Aunins et al. that now includes also the dynamic competition between tiRNAs and viral RNAs (vRNAs).

Intracellular modelling of HCV infection and tiRNAs

Recently Aunins et al. presented a detailed, parameterised intracellular model for hepatitis C viral (HCV) infection based on experimental data. The model consists of 6 steps (Fig. 1c). Step 1: positive-sense RNA strand in the cytoplasm [(+)-RNAcyt] binds to free ribosomes (RF (+)-RNAcyt) at a rate $k_{\text{init}}$, which synthesizes the viral polyprotein (PP) at a rate $k_{\text{ppsyn}}$. Step 2: the cleavage of PPs at a rate $k_{\text{psynth}}$ leads to production of structural proteins, including core protein (Cp) and nonstructural proteins, including NS3/4A, NS4A, and NS5B. Step 3: NS5B (polymerase) and NS5A bind to (+)-RNAcyt and host factor (HF) at rates $k_{\text{ppbind}}$ and $k_{\text{ppHF}}$ to form NS5B:(+)-RNA and HF complexes, respectively. These two complexes are imported into the vesicular membranous structure (VMS) at a rate $k_{\text{ppVMS}}$ in a second-order reaction. Step 4: the imported RNA forms a double-strand RNA (dsRNA) and releases NS5BVMS and HF at a rate $k_{\text{dsRNA}}$. Step 5: dsRNA binds to the NS5BVMS at a rate $k_{\text{dsRNA}}$ to synthesise (+)-RNAVMS at a rate $k_{\text{psynth}}$. Step 6: (+)-RNAVMS in the VMS are either exported into the cytoplasm at a rate $k_{\text{msrp}}$, or assembled into virions with 180 Cp and exported from the cell at a rate $k_{\text{assembly}}$. The model was fitted to experimental data and estimated parameter values (Table 1).

In this paper, we extend this model to include the dynamics of tiRNAs (Fig. 1c). Both the viral genome and tiRNA assemble via packaging signal (PS)-mediated assembly, i.e. both present PSs with affinity for viral Cp, ensuring efficient, specific genome packing. The PS distribution of the tiRNAs is optimised with respect to that of the virus, e.g. by stabilising key PSs in the distribution as in, enabling them to potentially assemble more efficiently than the virus (Fig. 1a). We consider tiRNAs which also contain the terminal sequences necessary for recognition by viral polymerases, so that they are replicated in the presence of the virus (Fig. 1b). As there is no protein coding requirement, and indeed no IRES, tiRNAs replication efficiency relative to the genome can be increased by shortening of the genome, or by tuning the nucleotide sequence. Thus, we model tiRNAs dynamics as follows: We assume that a positive-sense tiRNA in the cytoplasm [(+)-RNAVMS] binds to free ribosomes (RF (+)-RNAVMS) at a rate $k_{\text{init}}$, which synthesizes the viral polyprotein (PP) at a rate $k_{\text{ppsyn}}$. Then, similar to viral RNAs (vRNAs), they produce double-strand tiRNA and (+)-tiRNAVMS at rates $b_{1}k_{\text{init}}$ and $b_{2}k_{\text{psynth}}$, respectively, where $b_{1}$ characterises the replication efficiency of the tiRNAs. A tiRNA with $b_{1} = 1$ would be transcribed at the same rate as vRNAs. The newly formed (+)-tiRNAVMS is then either exported into the cytoplasm at a rate $k_{\text{msrp}}$ or assembled into TIPS with 180 Cp and exported from the cell at a rate $b_{2}k_{\text{assembly}}$, where $b_{2}$ characterises the assembly efficiency of the tiRNAs (Fig. 1c). The assembly efficiency of a tiRNA can be tuned by alteration of the PS distribution, for instance, a competition experiment between STNV and a copy with an optimised PS distribution resulted in encapsidation in a ratio of 1:2 to 1:3, suggesting that $b_{2} = 5$ is experimentally achievable. The reactions of the model are provided in Methods.

Aunins et al. used ordinary differential equations (ODE) to model the production of virions over a relatively short timescale (50 hours). In this work we derive a continuous-time Markov chain (CTMC) model from the ODE model and use the Gillespie algorithm as a discrete stochastic method for solving the CTMC model and plot stochastic trajectories. The mean over the stochastic trajectories plotted using the Gillespie algorithm is in excellent agreement with the ODE dynamics (Supplementary Figure S1 online). However, using the Gillespie method will also enable the tracking of individual particles, which is of particular interest at low concentrations during the initial kinetic phase. As the average life span of adult hepatocytes ranges from 200 to 300 days and since the half-life of HCV infected cells is estimated to be between 1.4 and 700 days, we ran our simulations for 100 days.

Results

Single cell viral dynamics.

Here we study the viral dynamics in the absence and presence of tiRNAs. The dynamics are computed as an average over 250 stochastic simulations of the reaction network using the Gillespie algorithm, implemented in Fortran and using parameter values from Table 1 and initially, with $b_{1} = 1$ and $b_{2} = 1$. The multiplicity of infection (MOI) is set to one vRNA and one tiRNA, consistent with data for intranasal sprays for clonal influenza DIPs. Figure 1d indicates the total number of released virions (solid red line) and
vRNAs in the cell (dashed red line) in the absence of co-infecting tiRNAs. Figure 1e shows the effect on viral dynamics of introducing tiRNAs. Co-infection with tiRNAs reduces the level of released virions by 70%. This reduction in the total number of released virions is called the treatment efficacy. It is here reached within 3 days, and remains within 2% of this value thereafter. The number of tiRNAs within the cell is comparable with the level of vRNAs in the tiRNA-free case. This shows that even without an advantage in replication or assembly, the lack of a protein-coding responsibility (and an IRES) enables tiRNAs to displace vRNAs as the most frequently packaged contents of new virus-like particles (VLPs).

The impact of the tiRNAs relies on two characteristic features: their relative replication ($b_r$) and assembly ($b_a$) efficiency compared with helper virus. We therefore investigate the impact of these two descriptors on the infection dynamics.

The effects of replication and assembly efficiencies. The assembly and replication efficiency of tiRNAs can be increased by adding more PSs into the genome, stabilising PSs or increasing their binding affinity, and shortening of the genome, respectively (Fig. 2a). Though many DVGs are well-known to have a replicative advantage over WT, probably due to their shorter genomes\cite{5,8,49}, the length of the genome is not the only factor that determines the replication efficiency ($b_r$)\cite{43,50}. Thus, we also consider the cases where $b_r < 1$, i.e., when tiRNAs are replicating less efficiently than WT virus. Figure 2b shows, for $b_r < 0.7$, that the efficacy of tiRNAs remains below 50%, even for high values of $b_a$ (assembly efficiency). This illustrates the importance of the replication process in the viral life cycle, as tiRNAs must be at least as efficient as WT virus at replication to be a viable treatment option. For $b_r \leq 1$, i.e. if tiRNAs are not more efficient at replication than virus, the total number of released particles is less than the control, while for $b_r = 2$ the total number of released particles is 3 times that of the control. (b) and (c) are plotted by averaging over 250 simulations with the initial condition (+)RNA$^{WT} = 1$, (+)tiRNA$^{WT} = 1$ and Cp = 360, using parameter values from Table 1.

Figure 2. The impact of replication and assembly efficiencies on the treatment efficacy and cumulative number of released virus-like particles. (a) TIP design is defined by two parameters: assembly efficacy $b_a$, which can be changed by addition of PSs in the tiRNAs (blue) compared with vRNA (red), and replication efficacy $b_r$, which can be improved by shortening of tiRNA with respect to vRNA. (b) The efficacy of tiRNAs (shown as the fraction indicating reduction in the number of released infectious virions) as a function of $b_a$ and $b_r$. (c) Pie charts for the cumulative number of released virions and TIPs after 100 days post infection. Red and blue indicate virions and TIPs, respectively. The tiRNA-free control is shown for comparison. The area of each graph is proportional to the total number of released particles (virus+TIP) with respect to the control. For $b_r \leq 1$ the total number of released particles is less than the control, while for $b_r = 2$ the total number of released particles is 3 times that of the control. (b) and (c) are plotted by averaging over 250 simulations with the initial condition (+)RNA$^{WT} = 1$, (+)tiRNA$^{WT} = 1$ and Cp = 360, using parameter values from Table 1.
Interestingly, the benefits of the treatment have a saturation point; increasing \( b_a > 10 \) and increasing \( b_r > 2 \) does not have a significant impact on the efficacy of the treatment and total number of released particles (Fig. 2b and c).

Even for \( b_a = b_r = 1 \), i.e. for equal replication and assembly efficiency as the virus, the number of released TIPs is higher than that of infectious virions. This is because tiRNAs have a competitive advantage over virus as they are depleting resources generated only by the virus, using virally generated polymerase for replication and Cp for assembly. In particular, during the time that vRNA is bound to ribosome, tiRNA is free to bind to NS5B and replicate at the expense of the virus, resulting in the inherent asymmetry between virus and TIP.

The effect of higher multiplicities of infection (MOIs).

The above results have been obtained in the equitable case of an MOI of 1:1. Experimental work on comparable systems have reported DIP MOIs in the range 1–1006, 39, 51. Therefore, we also consider cases with unequal starting proportions of vRNA and tiRNA. We determine the release kinetics for higher MOIs, setting \( b_a = b_r = 1 \) in order to isolate the effect of the MOI.

For MOIs of tiRNA (T) higher than the MOI of vRNA (V), the number of released virions decreases while increasing the ratio of TIPs/Virions (Fig. 3), with TIPs swiftly dominating the population. However, for MOIs of vRNA larger than that of tiRNA, a much smaller effect occurs (Fig. 3) and virions outnumber the TIPs, demonstrating that the relative ratio of virus and TIPs is important for the treatment outcome. From Fig. 3 we can see that when the MOI of tiRNA and vRNA is equal \( V = T = 1 \), the released particles are dominated by TIPs in, roughly, a 1.5:1 ratio with the virions. This suggests that in a population of infected cells, the subsequent infecions would also be seeded by MOIs with more tiRNAs than vRNAs, moving rightward in Fig. 3. This leads to a population of released particles dominated by non-infectious TIPs, potentially causing the elimination of the wider infection. A within-host model of an HCV infection in the presence of tiRNAs is required to fully examine the potential of this treatment strategy.

The effect of treatment start time.

The results presented above are based on the assumption that both the vRNAs and the tiRNAs begin the infection at the same time. However, this would not necessarily be the case in vivo. Figure 4 shows that if the MOI of tiRNA is larger than that of vRNA (blue shaded area), then the efficacy is higher than the average efficacy (solid black line). On the other hand, if the MOI of vRNA is larger than that of tiRNA (red shaded area), then the efficacy is lower than the average efficacy. If each cell being infected by a vRNA already harbours at least one tiRNA (start of treatment = 0 hour), we get the highest treatment efficacy (Fig. 4). However, if treatment was started (i.e. the tiRNAs introduced) after 24 h post infection, this treatment option has no significant effect on the outcome of the infection even if \( b_a, b_r \) are high and the MOI of tiRNAs is greater than that of the vRNAs. This is because there are more than 1,000 vRNAs in the cell, so that tiRNAs have little chance to overtake the viral life cycle (Fig. 4). This suggests that tiRNAs can be highly effective when used as a prophylactic antiviral treatment, an approach that has recently gained wider attention6, 52. Recent experiments for influenza DIPs have established that prophylactic intranasal treatment can achieve delivery of around one DIP per susceptible cell, where they can stay present for several weeks6. Although evaluation of the full impact of
TIPs as a treatment option during a chronic infection needs to be studied in the context of a within-host model, our model provides the foundation for studying such aspects by coupling the intracellular model presented here with an intercellular model in a multiscale approach53, 54.

Discussion

In this paper we have exploited recent insights into PS-mediated assembly in order to propose a novel design for TIPs that combines the replicative advantages of existing DIP/TIP strategies over viruses6, 11, 25 with the benefits of PS-mediated assembly. This novel design for TIPs opens up unprecedented therapeutic potential to interfere with viral replication and assembly, and misdirect viral resources. We have demonstrated the benefits of this combined strategy through stochastic simulations.

The tiRNA designs proposed here are alternatives to other therapeutic strategies exploiting PS-mediated assembly, such as small molecular weight compounds targeting the PS:RNA contacts. PS motifs are shared by viruses from the same family (e.g. in picornaviruses32, 55). Some viruses have been repurposed by nature for vital functions in the host organism. For instance, captured retroviruses and retrotransposons can be expressed in different tissues and at different points during life cycles, such as in neuronal functioning56, 57 or placentation58–61. Any PS-targeting drugs interfering with virus assembly in related viruses would therefore have to be monitored carefully with regards to their effect on other vital functions. tiRNAs, on the other hand, would not pose that risk.

However, they have the same benefits as PS-targeting drugs from the point of view of viral escape. This is because in both cases, viral escape would require mutation of the full set (or a significant subset) of the PSs, which would result in a significant intermittent fitness loss due to the multiple dispersed nature of the PSs62, making such a transition highly unlikely. The low propensity for therapy resistance is shared by other DIPs/ TIPs, where resistant strains have been shown to be selected against at both individual and population level25.

However, our tiRNA design has another advantage: Being stripped of all genetic information, these tiRNAs do not pose the risk of recombination. This is in contrast with DIPs that arise via deletion of a portion of the viral sequence, such as one genomic segment in the case of the multi-segmented influenza virus6, and that retain the coding capacity for some of the gene products.

As we demonstrate here, tiRNAs show promise as an effective treatment at the intracellular level, especially as a prophylactic treatment. Our intracellular model shows that in this case the tiRNA only needs to be as effective at packaging and replicating as vRNA to dominate the population of particles released from the infected cell. DVGs arising naturally in viruses that assemble via multiple dispersed packaging signals may have only a subset of the PS sites and therefore not be optimal at assembly; the possibility to de novo-engineer tiRNAs that not only are assembly-competent but are more assembly-efficient than WT, as well as having a replicative advantage, therefore constitutes a step-change for antiviral approaches for this group of viruses. As TIPs are indistinguishable from WT virus on the particle exterior, they can elicit an immune response (increasing antigen levels), thus priming the immune system against a subsequent infection. Multiscale within-host models of the immune response will be required to study the impact of this within infected patients, and analyse the impact of TIPs on both acute and chronic infections. Furthermore, models of between-host infection dynamics will reveal the consequences of any TIP transmission between hosts, and thus potentially reveal additional benefits to the host population arising from this. Such models would also enable evaluation of risks associated with the use of TIPs25, 37, 39.
**Methods**

**Reaction kinetics of the viral life cycle.** The first step is the production of polyprotein (PP) using the host cell ribosomes (Rib) from the (+)RNA in cytoplasm [(+)RNA<sup>cvt</sup>]:

\[
(+)\text{RNA}^{cvt} + \text{Rib} \xrightarrow{k_{nuc}} \text{R} (+)\text{RNA},
\]

\[
\text{R} (+)\text{RNA} \xrightarrow{k_{trans}} \text{PP} + \text{Rib} + (+)\text{RNA}^{cvt}.
\]

Then, the viral proteins are cleaved in a single reaction from the PP:

\[
\text{PP} \xrightarrow{k_{cleavage}} \text{Cp} + \text{NS3/4A} + \text{NS5A} + \text{NS5B}^{cvt}.
\]

In the next step, NS5A and NS5B<sup>cvt</sup> bind to human factor (HF) and (+)RNA<sup>cvt</sup> or (+)tiRNA<sup>cvt</sup>, respectively, and these two complexes are imported into the VMS in a second-order reaction:

\[
(+)\text{RNA}^{cvt} + \text{NS5B}^{cvt} \xrightarrow{k_{pib}} \text{NS5B} (+)\text{RNA},
\]

\[
(+)^{cvt}\text{tiRNA} + \text{NS5B}^{cvt} \xrightarrow{k_{pib}} \text{NS5B} (+)^{cvt}\text{tiRNA},
\]

\[
\text{HF} + \text{NS5A} \xrightarrow{k_{hf}} \text{HFC},
\]

\[
\text{NS5B} (+)\text{RNA} + \text{HF} \xrightarrow{k_{rp}} \text{NS5B} (+)^{cvt}\text{tiRNA}:\text{HFC},
\]

\[
\text{NS5B} (+)^{cvt}\text{tiRNA} + \text{HFC} \xrightarrow{k_{rp}} \text{NS5B} (+)^{cvt}\text{tiRNA}:\text{HFC}.
\]

The imported RNA (tiRNA) forms dsRNA (dstiRNA) and releases NS5B and HF:

\[
\text{NS5B} (+)^{cvt}\text{tiRNA}:\text{HFC} \xrightarrow{k_{init}} \text{VMS} + \text{dsRNA} + \text{HF},
\]

\[
\text{NS5B} (+)^{cvt}\text{tiRNA}:\text{HFC} \xrightarrow{k_{init}} \text{VMS} + \text{dsRNA} + \text{NF5B}^{VMS} + (+)^{cvt}\text{tiRNA}.
\]

Once again the dsRNA (dstiRNA) and NS5B<sup>VMS</sup> form a complex required to synthesise new (+)RNA<sup>VMS</sup> ((+)^{cvt}\text{tiRNA}<sup>VMS</sup>):

\[
\text{dsRNA} + \text{NS5B}^{VMS} \xrightarrow{k_{rip}} \text{NS5B} \text{dsRNA},
\]

\[
\text{dstiRNA} + \text{NS5B}^{VMS} \xrightarrow{k_{rip}} \text{NS5B} \text{dstiRNA},
\]

\[
\text{NS5B} \text{dsRNA} \xrightarrow{k_{rpl}} \text{dsRNA} + \text{NS5B}^{VMS} + (+)\text{RNA}^{VMS},
\]

\[
\text{NS5B} \text{dstiRNA} \xrightarrow{k_{rpl}} \text{dstiRNA} + \text{NS5B}^{VMS} + (+)^{cvt}\text{tiRNA}^{VMS}.
\]

(+)^{cvt}\text{RNA}^{VMS} ((+)^{cvt}\text{tiRNA}^{VMS}) are either exported into the cytoplasm or assembled into new virions (TIPs) with Cp:

\[
(+)^{cvt}\text{RNA}^{VMS} \xrightarrow{k_{export}} (+)^{cvt}\text{RNA},
\]

\[
(+)^{cvt}\text{tiRNA}^{VMS} \xrightarrow{k_{export}} (+)^{cvt}\text{tiRNA},
\]

\[
(+)^{cvt}\text{RNA}^{VMS} + 180 \text{Cp} \xrightarrow{k_{assembly}} \text{virion},
\]

\[
(+)^{cvt}\text{tiRNA}^{VMS} + 180 \text{Cp} \xrightarrow{k_{assembly}} \text{TIP}.
\]

Finally, we allow natural decay of vRNAs, tiRNAs, proteins and VMS via the reactions:

\[
(+)^{cvt}\text{RNA} \xrightarrow{k_{deg}} 0,
\]

\[
\text{NS5B} (+)^{cvt}\text{RNA}:\text{HFC} \xrightarrow{k_{deg}} 0,
\]

\[
\text{dsRNA} \xrightarrow{k_{deg}} 0,
\]

\[
(+)^{cvt}\text{RNA}^{VMS} \xrightarrow{k_{deg}} 0,
\]

\[
\text{NS5B} \text{dsRNA} \xrightarrow{k_{deg}} 0,
\]

\[
\text{NS5B}^{cvt} \xrightarrow{k_{deg}} 0,
\]

\[
\text{NS3/4A} \xrightarrow{k_{deg}} 0,
\]

\[
\text{NS5B}^{cvt} \xrightarrow{k_{deg}} 0,
\]

\[
\text{Cp} \xrightarrow{k_{deg}} 0.
\]


Table 1. Table of parameter values.

| Parameter | Value | Parameter | Value |
|-----------|-------|-----------|-------|
| $k_{degs}$ | 1 molecule$^{-1}$ h$^{-1}$ | $k_{trans}$ | 180 h$^{-1}$ |
| $k_{degns}$ | 9 h$^{-1}$ | $k_{rig}$ | 0.0008 molecule$^{-1}$ h$^{-1}$ |
| $k_{repl}$ | 0.1 molecule$^{-1}$ h$^{-1}$ | $k_{rep}$ | 0.6 molecule$^{-1}$ h$^{-1}$ |
| $k_{init}$ | 1.12 h$^{-1}$ | $k_{eub}$ | 10 molecule$^{-1}$ h$^{-1}$ |
| $k_{clev}$ | 1.12 h$^{-1}$ | $k_{outp}$ | 0.307 h$^{-1}$ |
| $k_{assem}$ | 1.2 × 10$^{-7}$ molecule$^{-1}$ h$^{-1}$ | $k_{degrp}$ | 0.26 h$^{-1}$ |
| $k_{degm}$ | 0.11 h$^{-1}$ | $k_{degs}$ | 0.001 h$^{-1}$ |
| Rib | 5000 molecules | HF | 30 molecules |
| $k_{degs}$ | 0.61 h$^{-1}$ from 0 to 21 h, and 0.1 h$^{-1}$ from 21 h onward |

Parameter values. We use parameter values that have been reported in Aunins et al. and are presented in Table 1.

Data availability
All data generated or analysed during this study are included in this published article (and its Supplementary Information file).

Accession codes
All codes are available in the authors' GitHub page: github.com/MathematicalComputationalVirology/HCVIntracellularModelling.

Received: 18 August 2021; Accepted: 22 November 2021
Published online: 13 December 2021

References
1. Huang, A. S. & Baltimore, D. Defective viral particles and viral disease processes. Nature 226, 325–327 (1970).
2. Poirier, E. Z. & Vignuzzi, M. Virus population dynamics during infection. Curr. Opin. Virol. 23, 82–87 (2017).
3. Li, D. Dengue virus-free defective interfering particles have potent and broad anti-dengue virus activity. Commun. Biol. 4, 557 (2021).
4. Vignuzzi, M. & López, C. B. Defective viral genomes are key drivers of the virus-host interaction. Nat. Microbiol. 4, 1075–1087 (2019).
5. Manzoni, T. B. & López, C. B. Defective (interfering) viral genomes re-explored: Impact on antiviral immunity and virus persistence. Fut. Virol. 13, 493–503 (2018).
6. Dimmock, N. J. & Easton, A. J. Defective interfering influenza virus RNAs: Time to reevaluate their clinical potential as broad-spectrum antivirals? J. Virol. 88, 5217–5227 (2014).
7. Rand, U. Antiviral activity of influenza A virus defective interfering particles against SARS-CoV-2 replication in vitro through stimulation of innate immunity. Cells 10, 1756 (2021).
8. Rezelj, V. V. et al. Synthetic defective interfering SARS-CoV-2 provides protection against pneumovirus infection in mammalian and mosquito hosts. Nat. Commun. 12, 2291 (2021).
9. Yao, S., Narayanan, A., Majowicz, S. A., Jose, J. & Archetti, M. A synthetic defective interfering SARS-CoV-2. PeerJ 9, e11686 (2021).
10. Dimmock, N. J. et al. Cloned defective interfering influenza virus protects ferrets from pandemic 2009 influenza A virus and allows protective immunity to be established. PLoS ONE 7, e49394 (2012).
11. Marriott, A. C. & Dimmock, N. J. Defective interfering viruses and their potential as antiviral agents. Rev. Med. Virol. 20, 51–62 (2010).
12. Easton, A. J. et al. A novel broad-spectrum treatment for respiratory virus infections: Influenza-based defective interfering virus provides protection against pneumovirus infection in vivo. Vaccine 29, 2777–2784 (2011).
13. Mann, A. et al. Interfering vaccine (defective interfering influenza A virus) protects ferrets from influenza, and allows them to develop solid immunity to reinfection. Vaccine 24, 4290–4296 (2006).
14. Noble, S., McLain, L. & Dimmock, N. J. Interfering vaccine: A novel antiviral that converts a potentially virulent infection into one that is subclinical and immunizing. Vaccine 22, 3018–3025 (2004).
15. Dimmock, N. & Easton, A. Anti-viral protection with viruses containing defective genome segments (2014). US Patent 8691215.
16. Dimmock, N. Method of preventing or treating influenza A viral infection using cloned DI influenza A viral particles (2015). US Patent 9089516.
17. Dimmock, N. Cloned defective interfering influenza A virus (2013). US Patent 8435508.
18. von Magnus, P. Incomplete forms of influenza virus. In Adv. Virus Res., vol. 2, 59–79 (Elsevier, 1954).
19. Giachetti, C. & Holland, I. J. Altered replicase specificity is responsible for resistance to defective interfering particle interference of an Sdi-mutant of vesicular stomatitis virus. J. Virol. 62, 3614–3621 (1988).
20. Huang, A. S. Defective interfering viruses. Annu. Rev. Microbiol. 27, 101–118 (1973).
21. Zwart, M. P. et al. Complex dynamics of defective interfering baculoviruses during serial passage in insect cells. J. Biol. Phys. 39, 327–342 (2013).
22. Metzger, V. T., Lloyd-Smith, J. O. & Weinberger, L. S. Autonomous targeting of infectious superspreaders using engineered transmissible therapies. PLoS Comput. Biol. 7, e1002015 (2011).
23. Nottan, T., Sardanyés, J., Weinberger, A. D. & Weinberger, L. S. The case for transmissible antivirals to control population-wide infectious disease. Trends Biotechnol. 32, 400–405 (2014).
24. Rouzine, I. M. & Weinberger, L. S. Design requirements for interfering particles to maintain coadaptive stability with HIV-1. J. Virol. 87, 2081–2093 (2013).
25. Rast, L. I. et al. Conflicting selection pressures will constrain viral escape from interfering particles: Principles for designing resistance-proof antivirals. *PLoS Comput. Biol.* **12**, e1004799 (2016).

26. Stockley, P. G., Ranson, N. A. & Twarock, R. A new paradigm for the roles of the genome in ssRNA viruses. *Future Virol.* **8**, 531–543 (2013).

27. Dykeman, E. C., Stockley, P. G. & Twarock, R. Packaging signals in two single-stranded RNA viruses imply a conserved assembly mechanism and geometry of the packaged genome. *J. Mol. Biol.* **425**, 3235–3249 (2013).

28. Stockley, P. G. et al. Packaging signals in single-stranded RNA viruses: nature's alternative to a purely electrostatic assembly mechanism. *J. Biol. Phys.* **39**, 277–287 (2013).

29. Rolffson, O. et al. Direct evidence for packaging signal-mediated assembly of bacteriophage MS2. *J. Mol. Biol.* **428**, 431–448 (2016).

30. Patel, N. et al. HBV RNA pre-genome encodes specific motifs that mediate interactions with the viral core protein that promote nucleocapsid assembly. *Nat. Microbiol.* **2**, 17098 (2017).

31. Stewart, H. et al. Identification of novel RNA secondary structures within the hepatitis C virus genome reveals a cooperative involvement in genome packaging. *Sci. Rep.* **6**, 22952 (2016).

32. Shakeel, S. et al. Genomic RNA folding mediates assembly of human parechovirus. *Nat. Commun.* **8**, 5 (2017).

33. Dykeman, E. C., Stockley, P. G. & Twarock, R. Solving a Levinthal's paradox for virus assembly identifies a unique antiviral strategy. *Proc. Natl. Acad. Sci. U. S. A.* **111**, 5361–5366 (2014).

34. Fatehi, F. et al. An intracellular model of hepatitis B viral infection: An in silico platform for comparing therapeutic strategies. *Viruses* **13**, 11 (2021).

35. Patel, N. et al. Rewriting nature's assembly manual for a ssRNA virus. *Proc. Natl. Acad. Sci. U. S. A.* **114**, 12255–12260 (2017).

36. Shirogane, Y. et al. Experimental and mathematical insights on the interactions between poliovirus and a defective interfering genome. *PLoS Pathog.* **17**, e0100927 (2021).

37. Kirkwood, T. B. L. & Bangham, C. R. M. Cycles, chaos, and evolution in virus cultures: A model of defective interfering particles. *Proc. Natl. Acad. Sci. U. S. A.* **91**, 8685–8689 (1994).

38. Bangham, C. R. M. & Kirkwood, T. B. L. Defective interfering particles: Effects in modulating virus growth and persistence. *Virolology* **179**, 821–826 (1990).

39. Thompson, K. A. S. & Yin, J. Population dynamics of an RNA virus and its defective interfering particles in passage cultures. *Virolology* **47**, 257 (2010).

40. Thompson, K. A. S., Rempala, G. A. & Yin, J. Multiple-hit inhibition of infection by defective interfering particles. *J. Gen. Virol.* **90**, 888–899 (2009).

41. Aunins, T. R. et al. Intracellular hepatitis C virus modeling predicts infection dynamics and viral protein mechanisms. *J. Virol.* **92** (2018).

42. Li, D. & Aaskov, J. Sub-genomic RNA of defective interfering (D.I.) Dengue viral particles is replicated in the same manner as full length genomes. *Virology* **468**, 248–255 (2014).

43. Lin, Y. J. & Lai, M. M. Deletion mapping of a mouse hepatitis virus defective interfering RNA reveals the requirement of an internal and discontinuous sequence for replication. *J. Virol.* **67**, 6110–6118 (1993).

44. Fatehi, F., Kyrychko, S. N., Ross, A., Kyrychko, Y. N. & Blyuss, K. B. Stochastic effects in autoimmune dynamics. *Front. Physiol.* **9**, 45 (2018).

45. Yuan, Y. & Allen, I. S. Stochastic models for virus and immune system dynamics. *Math. Biosci.* **234**, 84–94 (2011).

46. Gillespie, D. T. Exact stochastic simulation of coupled chemical reactions. *J. Phys. Chem.* **81**, 2340–2361 (1977).

47. Duncan, A. W., Dorrell, C. & Grompe, M. Stem cells and liver regeneration. *Gastroenterology* **137**, 466–481 (2009).

48. Dahari, H. et al. A mathematical model of hepatitis C virus dynamics in patients with high baseline viral loads or advanced liver disease. *Gastroenterology* **136**, 1402–1409 (2009).

49. Regez, V. V., Levi, L. I. & Vignuzzi, M. The defective component of viral populations. *Carr. Opin. Virol.* **33**, 74–80 (2018).

50. Thomson, M., White, C. L. & Dimmock, N. J. The genomic sequence of defective interfering Semliki Forest virus (SFV) determines its ability to be replicated in mouse brain and to protect against a lethal SFV infection in vivo. *Virology* **241**, 215–223 (1998).

51. Abrahao, J. et al. Tailored giant Tupanvirus possesses the most complete translational apparatus of the known virosphere. *Nat. Commun.* **9**, 749 (2018).

52. Czuppon, P. et al. Success of prophylactic antiviral therapy for SARS-CoV-2: Predicted critical efficacies and impact of different drug-specific mechanisms of action. *PLoS Comput. Biol.* **17**, e1008752 (2021).

53. Quintela, B. D. M. et al. A new age-structured multiscale model of the hepatitis C virus life-cycle during infection and therapy with direct-acting antiviral agents. *Front. Microbiol.* **9**, 601 (2018).

54. Fatehi, F., Bingham, R. J., Dykeman, E. C., Stockley, P. G. & Twarock, R. Comparing antiviral strategies against COVID-19 via multiscale within-host modelling. *R. Soc. Open Sci.* **8**, 210082 (2021).

55. Chandler-Bostock, R. et al. Assembly of infectious enteroviruses depends on multiple, conserved genomic RNA-coat protein contacts. *PLoS Pathog.* **16**, e1009146 (2020).

56. Pastuzyn, E. D. et al. The neuronal gene Arc encodes a repurposed retrotransposon Gag protein that mediates intercellular RNA transfer. *Cell* **172**, 275–288 (2018).

57. Ashley, J. et al. Retrovirus-like Gag protein ArcI binds RNA and traffics across synaptic boutons. *Cell* **172**, 262–274 (2018).

58. Groe, E. J. et al. Intrinsic retroviral reactivation in human preimplantation embryos and pluripotent cells. *Nature* **522**, 221 (2015).

59. Cornelis, G. et al. An endogenous retroviral envelope syncytin and its cognate receptor identified in the viviparous placental Mabuya lizard. *Proc. Natl. Acad. Sci.* **114**, E10991–E11000 (2017).

60. Cornelis, G. et al. Retroviral envelope gene captures and syncytin exaptation for placentation in marsupials. *Proc. Natl. Acad. Sci.* **112**, E487–E496 (2015).

61. Denner, J. Function of a retroviral envelope protein in the placenta of a viviparous lizard. *Proc. Natl. Acad. Sci.* **114**, 13315–13317 (2017).

62. Bingham, R. J., Dykeman, E. C. & Twarock, R. RNA virus evolution via a quasispecies-based model reveals a drug target with a high barrier to resistance. *Viruses* **9**, 347 (2017).

**Acknowledgements**

PGS and RT thank the Wellcome Trust for financial support through the Joint Investigator Award (110145 & 110146), which also provided funding for P-PD and FF. Moreover, RT thanks the EPSRC for an Established Career Fellowship (EP/R023204/1) and the Royal Society for a Royal Society Wolfson Fellowship (RSWF/R1/180009).

**Author contributions**

R.T., P.-P.D., and P.G.S. conceived the goals of the study. F.F. and R.J.B. conducted the analysis. F.F., R.J.B., R.T., and P.-P.D. analysed the results. All authors reviewed the manuscript.
Competition interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-03168-0.

Correspondence and requests for materials should be addressed to P.G.S. or R.T.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021